TCL1B: A Potential Drug Target and Biomarker for Syncytiotrophoblast-Specific Protein

Target Name: TCL1B

NCBI ID: G9623

TCL1B

TCL1B: A Potential Drug Target and Biomarker for Syncytiotrophoblast-Specific Protein

Syncytiotrophoblast-specific protein (TCL1B) is a protein that is expressed in high levels in the syncytiotrophoblast, which is a type of mesenchymal cell in the body. The syncytiotrophoblast is responsible for producing the extracellular matrix (ECM), which is a vital component of connective tissue, including bone, cartilage, and skin. ECM plays a crucial role in maintaining tissue structure and function, and alterations in the ECM can lead to various diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, understanding the role of TCL1B in ECM formation and its potential as a drug target or biomarker is of great interest.

TCL1B: Structure and Function

TCL1B is a 14kDa protein that is composed of 126 amino acid residues. It has a distinct N-terminus that is involved in its cytoplasmic localization and is followed by a variable region that includes several unique amino acids. The variable region is known as the T-loop, which is a conserved structural motif that is involved in protein-protein interactions. The T-loop is responsible for the formation of a disulfide bond, which is a common structural feature in proteins that helps to strengthen the bond between two proteins.

The second N-terminus of TCL1B is a unique region that is known as the C-loop. The C-loop is a conserved structural motif that is involved in the formation of a disulfide bond. It is composed of four amino acids, which are Gly-Pro-Asp-Gly. The C-loop is also responsible for the formation of a hydrogen bond with the Asp214 residue, which is part of the TCL1B protein.

The C-terminal region of TCL1B contains a 20 amino acid long terminal fragment (T-loop-like region) that is involved in the formation of a disulfide bond with the Asp214 residue. The T-loop-like region is composed of five amino acids, which are Asp-Gly-Asp-Gly-Pro-Gly. This region is important for the stability of the TCL1B protein and plays a role in its cytoplasmic localization.

TCL1B is expressed in a variety of tissues, including bone, cartilage, and skin, and it is involved in the production of the ECM. The ECM is a vital component of connective tissue, and it plays a crucial role in maintaining tissue structure and function. ECM is involved in various physiological processes, including cell adhesion, migration, and signaling. Therefore, alterations in the ECM can lead to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

TCL1B has been shown to be involved in the production of the ECM in various organisms, including mammals. For example, TCL1B has been shown to be involved in the production of the ECM in rat fetal bones. In addition, TCL1B has been shown to be involved in the production of the ECM in human tissue samples, including bone marrow, skin, and blood.

TCL1B as a Drug Target

TCL1B is a protein that has potential as a drug target due to its involvement in the production of the ECM. One of the potential strategies to target TCL1B is to use small molecules that can inhibit its activity in the production of the ECM. Such

Protein Name: TCL1 Family AKT Coactivator B

Functions: Enhances the phosphorylation and activation of AKT1 and AKT2

The "TCL1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCL1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets